Menu
1 min read · estimated
APPROVED USE
What FDA approved
Adults with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma and an FGFR2 fusion or other rearrangement.
LAMPGEN ANALYSIS
Why it matters
An FGFR inhibitor adds an option for a genomically selected intrahepatic bile duct cancer population.
What research teams should watch
Capture the exact rearrangement, disease site and prior systemic treatment. Track laboratory monitoring during treatment.
PRIMARY RECORDS